期刊文献+

老年2型糖尿病合并心血管病的病变特点及危险因素分析 被引量:3

Characteristics and risk factors of cardiovascular disease in elderly patients with type 2 diabetes mellitus
下载PDF
导出
摘要 目的观察佛山地区老年糖尿病合并心血管病患者的临床特征,并分析其危险因素。方法选取2014年2月至2016年2月间佛山市第一人民医院同济康复医院及佛山市第一人民医院收治的老年2型糖尿病患者1 877例为研究对象,其中600例合并心血管病患者为观察组,1 277例未合并心血管病患者为对照组,比较两组患者的临床资料,并以Logistic多元回归分析方法分析老年2型糖尿病患者合并心血管病的危险因素。结果观察组和对照组患者的糖尿病(DM)病程[(10.3±3.1)年vs(8.9±2.5)年]、吸烟年限[(19.1±6.2)年vs(16.5±6.6)年],体质量指数(BMI)(24.1±1.3 vs 23.3±1.1)比较,观察组均明显长于或大于对照组,差异均有统计学意义(P<0.05);观察组和对照组患者罹患脂肪肝(60.2%vs 54.2%)和脑血管病(56.2%vs 50.4%)的比例比较,观察组均明显高于对照组,差异均有统计学意义(P<0.05);观察组患者的总胆固醇(TC)、甘油三酯(TG)、纤维蛋白原(FIB)、空腹血糖(FBG)、2 h空腹血糖(2 h FBG)及糖化血红蛋白(Hb A1c)均明显高于对照组,高密度脂蛋白(HDL-C)、载脂蛋白A(Apo A)、水平明显低于对照组,差异均有显著统计学意义(P<0.01);Logistic多元回归分析结果显示,糖尿病病程、Hb A1c及吸烟年限是2型糖尿病合并心血管的独立危险因素(P<0.05)。结论 2型糖尿病合并心血管病的发生率高,随着糖尿病病程的延长、Hb A1C控制不良、吸烟年限的延长,其发生心血管病的危险性增加。 Objective To observe the clinical characteristics of diabetes mellitus complicated with cardiovascular disease in Foshan, and to analyze the risk factors. Methods A total of 1 877 patients with type 2 diabetes mellitus(T2DM), who admitted to Tongji Rehabilitation Hospital of the First People's Hospital of Foshan and the First People's Hospital of Foshan from February 2014 to February 2016 were selected as the subjects. Among them, 600 patients with cardiovascular disease were the observation group, and 1 277 patients with no cardiovascular disease were included in the control group. The clinical data of the two groups were compared, and logistic regression analysis was used to analyze the risk factors of cardiovascular disease in T2 DM patients. Results The DM course of disease, smoking years,BMI in the observation group were(10.3±3.1) years,(19.1±6.2) years,(24.1±1.3) years, respectively, which were significantly longer or higher than corresponding(8.9±2.5) years(16.5±6.6) years,(23.3±1.1) years in the control group(P〈0.05). The proportion of fatty liver and cerebrovascular disease of the observation group were respectively 60.2% and56.2%, which were significantly higher than 54.2% and 50.4% of the control group(P〈0.05). The levels of total cholesterol(TC), triglyceride(TG), fibrogen(FIB), fasting blood glucose(FBG), 2-h postprandial blood glucose(2 h PBG) and glycosylated hemoglobin(Hb A1c) in the observation group were significantly higher than those in the control group;the levels of high-density lipoprotein(HDL-C) and apolipoprotein A(apo A) were significantly lower than those of the control group(P〈0.01). Logistic multivariate regression analysis showed that the duration of diabetes, Hb A1 c and duration of smoking were independent risk factors of cardiovascular disease in T2DM(P〈0.05). Conclusion The incidence of cardiovascular disease in elderly T2 DM is high, and the risk of cardiovascular disease increases with
作者 钟菊 陈劲松 ZHONG Ju CHEN Jin-song(Department of Internal Medicine, Tongji Rehabilitation Hospital of the First People's Hospital of Foshan, Foshan 528000, Guangdong, CHINA Department of Endocrinology, the First People's Hospital of Foshan, Foshan 528000, Guangdong, CHINA)
出处 《海南医学》 CAS 2017年第16期2599-2601,共3页 Hainan Medical Journal
基金 广东省佛山市卫生和计生局医学科研课题(编号:20170179)
关键词 2型糖尿病 心血管病 缺血性 LOGISTIC分析 Type 2 diabetes mellitus(T2DM) Cardiovascular disease Ischemia Logistic analysis
  • 相关文献

参考文献8

二级参考文献63

  • 1潘长玉,中国区合作调查组.中国糖尿病控制现状——指南与实践的差距 亚洲糖尿病治疗现状调查1998,2001及2003年中国区结果介绍[J].国外医学(内分泌学分册),2005,25(3):174-178. 被引量:396
  • 2韩佳琳,马山英,董砚虎.餐后血糖调节与糖尿病心血管疾病并发症[J].国际内分泌代谢杂志,2006,26(3):173-175. 被引量:21
  • 3Heart Protection Study Collaborative Group, Jonathan Emberson, Derrick Bennett,et al. C -reactive protein concentration and the vascular benefits of statin therapy:an analysis of 20,536 patients in the Heart Protection Study [ J ]. Lancet ,2011,377 (9764) :469 - 476. 被引量:1
  • 4Goto Y,Hotta N? Shigeta Y, et al. Effects of an aldose reduc-tase inhibitor, epalrestat, on diabetic neuropathy. Clinical ben-efit and indication for the drug assessed from the results of aplacebo-controlled double-blind study. Biomed Pharmacother,1995, 49 r 269-277. 被引量:1
  • 5Hotta N,Akanuma Y,Kawamori R, et al. Long-term clinicaleffects of epalrestat, an aldose reductase inhibitor, on diabeticperipheral neuropathy: the 3-year, multicenter, comparativeAldose Reductase Inhibitor^Diabetes Complications Trial. Dia-betes Care, 2006, 29:1538-1544. 被引量:1
  • 6Ikeda T, Iwata K,Tanaka Y. Long-term effect of epalrestaton cardiac autonomic neuropathy in subjects with non-insulindependent diabetes mellitus. Diabetes Res Clin Pract, 1999,43:193-198. 被引量:1
  • 7Nakayama M, Nakamura J, Hamada Y, et al. Aldose reduc-tase inhibition ameliorates pupillary light reflex and F-wave la-tency in patients with mild diabetic neuropathy. Diabetes Care,2001, 24:1093-1098. 被引量:1
  • 8Ziegler D, Mayer P, Rathmann W, et al. One-year treatmentwith the aldose reductase inhibitor, ponalrestat, in diabeticneuropathy. Diabetes Res Clin Pract, 1991,14:63-73. 被引量:1
  • 9Gingliano D, Marfella R,Quatraro A, et al. Tolrestat for milddiabetic neuropathy. A 52-week, randomized> placebo-con-trolled trial. Ann Intern Med, 1993,118:7-11. 被引量:1
  • 10Giugliano D, Acampora R, Marfella R, et al. Tolrestat in theprimary prevention of diabetic neuropathy. EHabetes Care,1995,18-536-541. 被引量:1

共引文献51

同被引文献22

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部